Literature DB >> 23103102

[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].

J Alberto Arranz Caso1, Elena Flores Ballester, Stephanie Ngo Pombe, Victor López Pizarro, José Luis Dominguez-Mompello, Andrés Restoy Lozano.   

Abstract

BACKGROUND AND
OBJECTIVE: Bisphosphonate related osteonecrosis of the jaw (BRONJ) has raised considerable interest since its recent description. Its pathogenesis is not yet clarified; formerly it has been considered a non-infectious complication, but recent studies seem to implicate bacteria of the genus Actinomyces. The objective of this study is to analyze the cases of BRONJ in our institution. PATIENTS AND METHODS: Review of medical records of patients diagnosed of BRONJ in the Maxillofacial Surgery Unit of our hospital.
RESULTS: We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid. All of them showed bone invasion by bacteria of the genus Actinomyces. Nine patients underwent prolonged treatment with amoxicillin with favourable clinical outcome in all of them, but 3 died of their malignancy. By contrast, one patient with beta-lactamic allergy and irregular treatment with erythromycin and tetracycline had a chronic evolution of the lesions. There was no information for other patient.
CONCLUSIONS: Actinomyces play an important role in the development of BRONJ and specific antibiotic treatment improves the prognosis of this process.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103102     DOI: 10.1016/j.medcli.2012.05.039

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  9 in total

1.  Sequestrum with actinomycosis.

Authors:  Yu-Hsueh Wu; Huai-Kuan Huang; Ming-Jay Hwang; Chun-Pin Chiang
Journal:  J Dent Sci       Date:  2022-05-11       Impact factor: 3.719

2.  [Vertebral osteomyelitis due to Actinomyces: a case report].

Authors:  B N Brizzi; C Fernández Alonso; A Nieto Sánchez; J González Del Castillo
Journal:  Rev Esp Quimioter       Date:  2018-01-26       Impact factor: 1.553

3.  Submental Perforator Flap for Soft-Tissue Reconstruction in Bisphosphonate-Related Osteonecrosis of the Jaws.

Authors:  Jose-Antonio García-de Marcos; Juan Rey-Biel
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2016-11-01

Review 4.  Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link?

Authors:  J De Ceulaer; E Tacconelli; S J Vandecasteele
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-01       Impact factor: 3.267

5.  Summary of the various treatments for osteonecrosis of the femoral head by mechanism: A review.

Authors:  Cheng Wang; Jiang Peng; Shibi Lu
Journal:  Exp Ther Med       Date:  2014-06-26       Impact factor: 2.447

6.  Targeted histological evaluation shows high incidence of actinomyces infection in medication-related osteonecrosis of the jaws.

Authors:  Andrea Brody; Bálint Scheich; Csaba Dobo-Nagy
Journal:  Sci Rep       Date:  2022-03-01       Impact factor: 4.996

7.  Sonication versus the conventional method for evaluation of the dental microbiome: a prospective pilot study.

Authors:  Oliver Wagendorf; Peter Menzel; Rolf Schwarzer; Norbert Neckel; Saskia Preissner; Max Heiland; Susanne Nahles
Journal:  BMC Oral Health       Date:  2022-08-12       Impact factor: 3.747

8.  Porphyromonas gingivalis Induces Bisphosphonate-Related Osteonecrosis of the Femur in Mice.

Authors:  Shuxuan Wu; Feng Li; Jingjing Tan; Xiaoling Ye; Yushi Le; Nianke Liu; Vincent Everts; Qilong Wan
Journal:  Front Cell Infect Microbiol       Date:  2022-06-22       Impact factor: 6.073

9.  Gut microbiota alterations associated with reduced bone mineral density in older adults.

Authors:  Mrinmoy Das; Owen Cronin; David M Keohane; Edel M Cormac; Helena Nugent; Michelle Nugent; Catherine Molloy; Paul W O'Toole; Fergus Shanahan; Michael G Molloy; Ian B Jeffery
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.